Search

Your search keyword '"Wach, S"' showing total 332 results

Search Constraints

Start Over You searched for: Author "Wach, S" Remove constraint Author: "Wach, S"
332 results on '"Wach, S"'

Search Results

2. The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer

3. MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer

7. Expression of GP88 (progranulin) in serum of prostate cancer patients is associated with Gleason scores and overall survival

12. Präoperative Identifikation von Hochrisikopatienten zur Prädiktion von funktionellem Outcome und Mortalität mithilfe eines komprehensiven geriatrischen Assessments – multizentrische Validierung des Erlangen Index

14. Serum miRNAs unterstützen die Entscheidungsfindung bezüglich einer Prostatastanzbiopsie speziell bei Patienten mit niedrigen PI-RADS scores

21. Heterogeneity-analysis of molecular subtypes of muscle-invasive bladder cancer and their precursor lesions in multiregion mapped whole-organ bladders

22. Bladder tumor subtype commitment occurs in carcinoma in-situ driven by key signaling pathways including ECM remodeling

26. Oncogenic signaling pathways in the Cancer Genome Atlas

27. Die Expression des GP88 (Progranulin) Proteins ist ein unabhängiger Prognosefaktor für Prostatakarzinom-Patienten

28. Der Erlanger Index (EI): Ein einfaches Assessment-Tool zur Prädiktion von funktionellem Outcome und Mortalität nach urologischen Tumoroperationen bei alten Patienten

29. Prognostische Rolle von FGFR-Alterationen und FGFR-mRNA-Expression bei Patienten mit metastasiertem Urothelkarzinom unter immunonkologischer Therapie

30. Heterogeneity-analysis of molecular subtypes of muscle-invasive bladder cancer and their precursor lesions in multiregion mapped whole-organ bladders

33. Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting

35. Geriatrisches Assessment vor urologischen Tumoroperationen als Prädiktoren von Komplikationen, funktionellem Outcome und Mortalität

36. Co-staining of microRNAs and their target proteins by miRNA in situ hybridization and immunohistofluorescence on prostate cancer tissue microarrays

37. Erratum: The Immune Landscape of Cancer (Immunity (2018) 48(4) (812–830.e14), (S1074761318301213), (10.1016/j.immuni.2018.03.023))

40. Die Piwi-like 1 Proteinexpression ist ein prognostischer Faktor

41. Cytotoxic T-Cell related gene expression signature predicts improved outcome in muscle-invasive urothelial bladder cancer patients following radical cystectomy and adjuvant chemotherapy

44. Serum mikroRNA-unterstützte, transrektale MRT-TRUS-Fusionsbiopsie der Prostata. Diagnostische Wertigkeit und prädiktive Aussagekraft

45. Comparative analysis of tumour mutational burden (TMB) prediction methods and its association with determinants of the tumour immune microenvironment of urothelial bladder cancer (UBC)

46. Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting

47. Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial

48. Tumor immune microenvironment drives prognostic relevance correlating with bladder cancer subtypes

49. Cytotoxic T cell related gene expression signature predicts improved outcome in muscle-invasive urothelial bladder cancer patients following radical cystectomy and adjuvant chemotherapy

50. Performance of FDA/EMA approved PD-L1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab

Catalog

Books, media, physical & digital resources